Previous Article | Next Article 
Journal of Clinical Microbiology, March 2001, p. 1036-1041, Vol. 39, No. 3
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1036-1041.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Canine Coronavirus Strains from Feces
by S Gene Nested PCR and Molecular Characterization of a New
Australian Isolate
Matthew J.
Naylor,1,*
Gavan A.
Harrison,1
Robert P.
Monckton,2
Steven
McOrist,3
Philip R.
Lehrbach,2 and
Elizabeth M.
Deane1
School of Science, University of Western
Sydney, Nepean, Kingswood, New South Wales,
2747,1 Fort Dodge Australia Pty
Limited, Baulkham Hills, New South Wales, 2153,2
and Veterinary Pathology Services Pty Limited, Glenside,
South Australia 5064,3 Australia
Received 8 September 2000/Returned for modification 5 November
2000/Accepted 21 December 2000
 |
ABSTRACT |
A nested PCR (nPCR) assay for the detection of canine
coronavirus (CCV) in fecal samples is described. The target sequence for the assay was a 514-bp fragment within the spike (S) glycoprotein gene. The sensitivity of the assay is extremely high, detecting as
little as 25 50% tissue culture infective doses per g of unprocessed feces. A clinical trial using dogs challenged orally with CCV SA4 and
CCV NVSL was used to compare viral isolation and the nPCR assay as
detection techniques over a 2-week period of infection. Virus isolation
detected CCV shedding from day 4 to 9 postchallenge, while the nPCR
assay detected CCV shedding from day 4 to 13 postchallenge. Cloning and
sequencing of the nPCR assay product enabled investigation of the
evolutionary relationships between strains within the S gene. The
simple and rapid procedure described here makes this assay an ideal
alternative technique to electron microscopy and viral isolation in
cell culture for detection of CCV shedding in feces. The described
assay also provides a method of identifying new strains of CCV without
the complicated and time-consuming practice of raising antibodies to
individual strains. This is illustrated by the identification, for the
first time, of an Australian isolate of CCV (UWSMN-1).
 |
INTRODUCTION |
Canine coronavirus (CCV) is a
single-stranded, positive-sense RNA viral pathogen of dogs that usually
produces symptoms varying from mild to moderate gastroenteritis
(1-3, 20, 26). In young or stressed animals, or in
combination with other pathogens such as canine parvovirus, symptoms
are more severe or fatal (1). Serological testing of
antibodies by serum neutralization (15) or indirect
enzyme-linked immunosorbent assay (ELISA) (19, 27) provides an indication of the exposure of an animal to CCV. Detection of anti-CCV immunoglobulin M (IgM) and anti-CCV IgG class
immunoglobulins by indirect ELISA (16, 26) enables current
or previous exposure to CCV, respectively, to be determined. However,
definitive identification of CCV-induced disease can only be
established by the identification of CCV shedding in feces by either
electron microscopy or virus isolation in cell culture. This situation
is further complicated by the fact that many workers have experienced
difficulties in cultivating coronaviruses in vitro (5,
29).
The PCR has been utilized as a detection technique for canine viral
pathogens such as canine parvovirus from feces (10, 22,
28). A nested PCR (nPCR) assay has also been described for
feline infectious peritonitis virus (7), a closely related coronavirus, and more recently an nPCR assay for the detection of CCV
based on primers to the transmembrane protein M gene has been described
(17).
The S gene of the coronavirus family has a variable region close to the
5' end and is involved in antigenic differences between strains (for a
review, see reference 20). Recombinant strains of
coronavirus exist that have a spike (S) gene originally derived from coronaviruses of other species (9). While
coronaviruses are known to undergo frequent recombination events in
vitro (12, 13), the frequency of these occurrences in the
field is unknown, but such events are suspected to be an important
means of avoiding host immunity (9).
In Australia, as elsewhere, field samples of CCV have been found to be
difficult to culture, with several failed attempts having been reported
(6, 14, 21). Despite identification of CCV and
coronavirus-like particles with electron microscopic studies of fecal
samples from Australian dogs (6, 14, 21), the prevalence
of CCV in the Australian dog population has only recently been firmly
established using indirect ELISA to detect anti-CCV IgG and IgM
antibodies (16). However, without cultivation of CCV,
determination of specific strains responsible for enteric outbreaks is
difficult. Thus, based on known DNA sequences of the CCV S protein gene
(30), we describe here the development of an nPCR assay
for the detection and identification of different CCV strains from
feces. This has allowed detection of a novel CCV isolate from an
Australian dog with fatal gastroenteritis.
 |
MATERIALS AND METHODS |
Virus and cells.
Crandell feline kidney (CRFK) cells
originally derived from domestic cat kidney (4) were
obtained from Fort Dodge Laboratories, Fort Dodge, Iowa. CCV strains
NVSL, SA4 and TN449 were also obtained from Fort Dodge Laboratories
(from master seed stock) and were used at passage <20.
Cell culture.
CRFK cells were propagated in growth medium
containing essential minimum Earl salts medium (EMEM) (Trace
Biosciences, Sydney, Australia), 2 mM L-glutamine, 0.05%
lactalbumin hydrolysate and 10% fetal bovine serum, not inactivated
(FBSNI) (CSL Biosciences, Melbourne, Australia). Maintenance medium for
maintaining confluent cells consisted of EMEM, 2 mM
L-glutamine, 0.05% lactalbumin hydrolysate and 5% FBSNI.
CCV clinical trial.
Specific-pathogen-free dogs were
maintained for a period of 1 year and were bled weekly. Titers of
antibody to CCV were determined by indirect ELISA, with all dogs found
seronegative to CCV over the 52-week period (data not shown). At 52 weeks, each animal was challenged orally with a viral titer of
108 50% tissue culture infective doses
(TCID50)
an equal mixture of CCV SA4 and CCV NVSL.
Specimen processing.
Feces were collected daily, 2 days
before oral challenge, and for a period of 14 days postchallenge. Fecal
samples were prepared for both virus isolation and RNA extraction as a
10% suspension in maintenance media. The sample was centrifuged for 5 min at 3,000 × g before serial filtration through
0.8-, 0.45-, and 0.2-µm-pore-size Minisart filters (Sartorius AG,
Goettingen, Germany), and stored at
70°C.
Field survey.
Feces were collected from 15 dogs suspected of
having CCV infection. In the case of field sample UWSMN-1, blood,
feces, and fresh and formalin-fixed tissue specimens were collected at
necropsy following fatal gastroenteritis in an 8-week-old pup.
Virus isolation.
Virus isolation and titration were
performed by inoculating 10
1 to 10
7
dilutions of processed fecal samples onto 96-well microtitration cell
culture plates (Nunc, Roskilde, Denmark) seeded with CRFK cells at
80% confluency and incubated for 48 h at 37°C in a
CO2 (4 to 6%) incubator. Plates were fixed with 80%
acetone for 30 min at
20°C, dried at room temperature, and
stained with 50 µl of 1:100 anti-CCV direct fluorescent
antibody conjugate (American BioResearch, Sevierville, Tenn.) per well
for 30 min at 37°C in a CO2 (4 to 6%) incubator. The
fluorescent antibody was decanted, and plates were washed three times
with rinse buffer (27 µM Na2CO3, 100 µM
NaHCO3 and 36 µM NaCl) before being scored for the
presence of CCV. The tissue culture infectious dose (TCID50
per milliliter) at 50% was determined as previously described
(8).
RNA isolation.
RNA was isolated from the processed fecal
samples using Total RNA isolation reagent (Advanced Biotechnologies,
Surrey, United Kingdom), following the manufacturer's instructions.
cDNA synthesis was performed using avian myeloblastosis virus reverse
transcriptase (Promega, Madison, Wis.) according to the manufacturer's
instructions, with the exception of using 1 µl of RNA preparation
with 125 pmol of CCVR1 primer in place of oligo(dT) primer.
nPCR assay.
PCR primers were chosen for conserved sites
flanking regions of variability on the basis of mismatch to other CCV
and feline coronavirus (FoCV) species within the S gene. First-round
PCR was performed using primers CCVF1
(TAATGTGACACAAYTGCCTGGCAATG [positions 201 to 227])
and CCVR1 (CTGTAGAAACTYGACTCACTCACTG [positions 1261 to 1286]). Primers CCVF2 (GTACTGGCAATGCAMGWGGTAAACC
[positions 403 to 428]) and CCVR2 (ACRTTGGTNGCATAGCCAGTGCA
[positions 895 to 917]) were used for second-round
amplification. Numbering is from the 5' end of the S gene of CCV-K378,
according to that of Wesseling et al. (30) (note: Y = C or T; R = A or G; N = A, G, C, or T; W = A or T). PCRs
were performed in a 50-µl reaction volume containing 5 µl of cDNA,
25 mM MgCl2, 5 µl of 10× PCR buffer (containing 100 mM
Tris-HCl and 500 mM KCl), 54 pmol of each primer, a 200 µM
concentration of each deoxynucleoside triphosphate, and 3.5 U of
Ampli Taq Gold enzyme (Perkin-Elmer, Foster City, Calif.). The
temperature regimen consisted of a 94°C 10-min denaturation cycle
followed by 94°C for 25 s, 58°C for 30 s, and 72°C for
2 min, for 33 cycles. An elongation step of 72°C for 5 min ended the
PCR. The product of the first-round PCR was diluted 1:50 with nuclease-free water (Promega), and 5 µl was used in the second-round amplification. Cycling conditions for the second PCR were identical to
those described for the first-round amplification.
The final amplified products were detected by electrophoresis through a
1.2% agarose gel in 1× TBE (90 mM Tris-borate and 2 mM EDTA) running
buffer. The gel was then stained in a solution of ethidium bromide (10 g/ml) and photographed under UV light.
The specificity of the designated primers was examined using
CCV-TN449-infected CRFK cells 48 h postinfection and noninfected CRFK control cells. Optimization of the nPCR assay was performed using
feces from dogs, 5 days post-CCV SA4 and CCV NVSL oral
challenge as a positive control and using feces from pre-viral
challenge specific-pathogen-free dogs as a negative control. The
analytical sensitivity of the assay was determined using CCV serially
diluted in feces from noninfected pups.
DNA sequencing.
The PCR products were purified from agarose
gels using a Bresa-Clean DNA purification kit (Geneworks, Adelaide,
Australia). DNA was cloned using the pGEM-T easy Vector system II
(Promega) according to the manufacturer's instructions. Nucleotide
sequencing was performed in both orientations by automated sequencing
at Newcastle DNA (University of Newcastle, Newcastle, Australia).
Sequence analysis.
Alignments of the DNA sequences from
different CCV strains were made using the PILEUP program of the
Genetics Computer Group package through the Australian National Genomic
Information Service (Sydney University, Sydney, Australia). Percentage
identities were calculated using the HOMOLOGIES program from the same
package. A DNA parsimony phylogenetic tree was constructed by first
using the Genetics Computer Group implementation of the PHYLIP package, ESEQBOOT, to generate 1,000 bootstrap sampling data sets and then analyzing these with the EDNAPARS program to find the most parsimonious trees. A consensus tree was constructed from these data using the
ECONSENSE program of the PHYLIP package.
Nucleotide sequence accession number.
The sequence of the S
gene product for CCV UWSMN-1 has been deposited in GenBank and assigned
accession number AF327928.
 |
RESULTS |
The nPCR assay demonstrated increased sensitivity in
comparison to PCR performed using only first-round primers CCVF1
and CCVR1 (Fig. 1). After second-round
amplification, the nested product appears as a 514-bp
fragment (Fig. 1).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of PCR and nPCR amplification of different
cell culture-propagated CCV strains, processed as described in
Materials and Methods. First-round amplification resulted in the
predicted 1,083-bp product, while second-round amplification produced a
514-bp product. Lane 1, CCV SA4; lane 2, CCV NVSL; lane 3, water
control; lane 4, negative control (noninfected CRFK cells); lane 5, CCV
TN449 (low titer); lane 6, CCV TN449 (high titer).
|
|
Serial dilutions of CCV-infected fecal samples were used to determine
the limit of sensitivity of the nPCR assay, which was found to be 2.5 TCID50 per reaction (Table
1). A detection limit of 2.5 TCID50 of virus per reaction approximately corresponds to a
viral titer of 25 TCID50 per g of unprocessed feces. The primers were designed on conserved regions within the S protein gene of
a consensus of CCV and FoCV. The assay demonstrated the ability to
detect serological variants of CCV, including CCV strains TN449, SA4,
and NVSL (Fig. 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Detection limit of nPCR assay determined with
CCV-spiked fecal samples as described in Materials and Methods
|
|
To confirm that the nPCR assay could be used as a suitable diagnostic
field test, we compared virus isolation and the nPCR assay using
experimentally infected pups over a 2-week period post-viral challenge.
Virus isolation technique detected CCV in the feces of the two dogs
examined from day 4 postchallenge up to day 9 (Table
2). The nPCR assay also detected the
commencement of CCV shedding again from day 4 up to day 9 but could
also detect viral shedding intermittently up to day 13. On nine
occasions, CCV was detected by the nPCR assay when viral
particles were not detected by isolation techniques (Table 2).
Comparison of the nPCR assay and viral isolation techniques was also
performed in a preliminary field screen of dogs demonstrating signs of
potential CCV infection or of animals from sites of recent gastroenteric disease outbreaks. Of the 15 dogs examined in the preliminary field screen, all dogs were found negative for CCV by virus
isolation in CRFK cells. In contrast, the nPCR assay detected CCV in
the feces from 1 of the 15 dog field samples. Isolate UWSMN-1 was
obtained from an 8-week-old pup presented with fatal gastroenteritis
during an outbreak of diarrhea in commercial breeding premises.
To establish nPCR assay specificity for CCV, sequencing of the nPCR
product from field sample UWSMN-1 and positive control samples (CCV
TN449, CCV NVSL, and CCV SA4) was performed. Sequencing identified CCV
S-gene-specific sequences (Fig. 2).
UWSMN-1 contains a codon (AAC) insertion at position 82, which results
in the deduced insertion of an asparagine residue between aspartic acid
and arginine residues which are conserved in other CCV and FoCV
strains. UWSMN-1 also contains a 1-bp deletion at position 444 (Fig. 2)
in relation to other CCV strains, and this leads to the 10 deduced
amino acids at the end of the sequence being very different from those
in other CCVs (Fig. 3).

View larger version (92K):
[in this window]
[in a new window]
|
FIG. 3.
Amino acid sequence alignment of nPCR assay S gene
product for CCV 1-71 (AF116246), CCV NVSL (AF116244), CCV K378
(X77047), CCV 6 (A22882), CCV C54 (A22886), CCV INSAVC (D13096), CCV
5821 (AB017789), CCV TN449 (AF116245), CCV UCD2 (AF116245), FoCV (FECV)
79-1683 (X80799), feline infectious peritonitis virus 79-1146
(X06170), and CCV UWSMN-1 (AF327928) (GenBank accession numbers are
denoted in parentheses). Shaded regions indicate amino acid residues
conserved among the different CCV and FoCV strains. Variable regions of
the consensus sequence are indicated by white boxing.
|
|
To examine the relationships between the Australian strain of CCV and
other previously described strains of CCV within the S gene, the
percentage identities between the different strains of CCV were
calculated (Fig. 4). The Australian field
sample had the least amount of identity to any of the other strains,
with only 86.1% homology to its most closely related strains, CCV NVSL and CCV 1-71 (Fig. 4). Phylogenetic analysis was performed to create an
unrooted tree of the relationships between different CCV strains.
This tree is based on DNA rather than protein parsimony as it was felt
that the frameshift mutation in the Australian isolate sequences
mentioned above would bias the relationships. The tree (Fig.
5) shows that the S gene sequences of
most of the coronavirus strains cluster into two main clades that
correspond to typical CCV and FoCV types. Note that S gene
sequences of several CCV strains (UCD-2, TN449, and 5821) are
grouped with the FoCVs in this tree. This close relationship between S
gene sequences of some CCV and FoCV strains has previously been noted,
and it has been proposed that this has arisen from recombination
between CCV and FoCV strains (9, 11, 29).
Interestingly, the Australian field isolate forms a
discrete branch which is intermediate between those of the CCV and FoCV
S gene sequences.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Percentage of nucleotide identity between the S gene
variable region sequence of CCV strain UWSMN-1 and other CCV and FoCV
strains denoted in Fig. 3.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Phylogenic tree of CCV and FoCV S gene sequences based
on DNA parsimony using the PHYLIP package as described in the Materials
and Methods. Bootstrap values indicate the number of times out of 1,000 iterations that a branch point was identified.
|
|
 |
DISCUSSION |
The nPCR assay described in this study was based on primer sites
within conserved regions of the S gene that flank a region of
variability. It was hypothesized that by basing primer design on
conserved regions, the assay would be able to detect a variety of
serologically different CCV strains. This proved correct as the assay
was able to detect several different strains of CCV, including TN449,
NVSL, SA4, and an Australian field strain (UWSMN-1). Sequencing
confirmed the assay's ability to amplify CCV-specific products, and
the relatively low identity between the Australian field strain
and the other well-characterized strains further demonstrates that the
assay is able to detect diverse strains of CCV, while still providing
informative sequence data for distinguishing closely related strains.
The sensitivity of this nPCR assay is comparable to that of other
coronavirus nPCR assays (7, 17). With a detection limit of
25 TCID50 per g of unprocessed feces, the assay is
approximately 4 × 104 times more sensitive than
electron microscopy, which has a reported detection limit of
approximately 106 particles per g of unprocessed feces
(18). Sequencing of the PCR product positively identifies
CCV-specific products, avoiding the possibility of false-positive
results commonly associated with electron microscopy.
Epidemics of CCV in kennels have been reported worldwide (3, 16,
19, 24), and chronic infection of animals has been proposed as a
source for persistent reinfection in colonies (25). CCV
has been demonstrated to be shed intermittently (26). We detected CCV shedding from day 4 postchallenge up to day 9 by virus
isolation, whereas intermittent viral shedding up to 13 days
postchallenge was detected by the nPCR assay. The ability of the nPCR
assay to detect viral shedding beyond the detection limit of viral
isolation demonstrates the increased sensitivity of the assay over
viral isolation techniques in the detection of field isolates.
The application of the nPCR assay to the preliminary field screen
further demonstrates the advantages of the nPCR assay as a CCV
detection technique. In the example of case UWSMN-1, the animal
presented with fatal gastroenteritis, unlike some previous descriptions
of the mild disease normally associated with CCV infection. Without
detection of viral shedding, it is difficult to conclude whether CCV is
the causative agent of gastroenteritis, as mixed viral infections may
occur (1, 16). CCV infection may also be confused with
canine parvovirus infections as they display broadly similar clinical
and pathological features. To further clarify the presence of CCV
infection we examined fecal and intestinal cellular material for the
presence of CCV by both virus isolation and nPCR assay techniques.
Virus isolation failed to identify CCV, as did further attempts to
cultivate CCV from these samples. However, CCV was identified by the
nPCR assay. The identification of CCV shedding identifies CCV as a
possible cause of canine gastroenteritis in Australia.
It is known that coronavirus recombinations occur frequently in vitro
(12, 13). There is also growing evidence that coronavirus recombinations also occur in the field, although the frequency of these
events is unknown. FoCV type II strains (79-1683 and 79-1146)
have been demonstrated as arising from double recombination events
between FoCV type I strains and CCV (9). The FoCV
type II strains have CCV-like S genes, and the authors speculated that the transfer of these genes may provide some sort of growth advantage or escape from immune response (9). Recently, the S gene
of CCV strain UCD-1 was shown to be more closely related to those of
porcine transmissible gastroenteritis virus rather than CCV strains
(29). CCV 5821 was also found to have an S gene more closely related to those of FoCV (11), suggesting that
recombinant CCV strains may also occur in the field. Therefore, one
possible explanation for the intermediate relationship of the
Australian CCV strain UWSMN-1 revealed in our phylogenetic tree is that
the S genes of this strain have arisen by homologous recombination between CCV and FoCV. However, if this were a relatively recent event
then these sequences would be expected to share discrete blocks of
homology with either the typical CCV or FoCV S sequences. As
indicated in Fig. 3, this is not the case, as the differences between
UWSMN-1 and the CCVs and FoCVs are widely dispersed, and therefore
UWSMN-1 does not appear to simply represent a chimera between CCV
and FoCV sequences. This finding is more consistent with the Australian
field isolate being relatively distantly related to other CCVs. It is
tempting to speculate that UWSMN-1 could represent sequences from the
coronavirus-like particles that have been described in two electron
microscopic studies in Australia rather than classic CCVs. However,
confirmation of these notions will require further investigation,
including sequencing of other regions from these isolates and viral
isolation. The assay described herein provides a diagnostic test that
can be used to diagnose CCV infection and monitor the divergence and
evolution of field strains responsible for epidemic outbreaks, without
the need for cultivation or raising of antibodies against specific strains.
 |
ACKNOWLEDGMENTS |
M. J. Naylor was supported by a Cooperative Education for
Enterprise Development grant funded by Fort Dodge Australia Pty Ltd and
the University of Western Sydney, Nepean, Australia.
 |
FOOTNOTES |
*
Corresponding author. Present address: Development
Group, Cancer Research Program, The Garvan Institute of Medical
Research, St. Vincent's Hospital, Sydney, New South Wales 2010, Australia. Phone: 61 2 92958343. Fax: 61 2 92958321. E-mail:
m.naylor{at}garvan.unsw.edu.au.
 |
REFERENCES |
| 1.
|
Appel, M. J. G.
1988.
Does canine coronavirus augment the effects of subsequent parvovirus infection?
Vet. Med. Small Anim. Clin.
83:360-366.
|
| 2.
|
Binn, L. N.,
E. Lazar,
K. P. Keenan,
D. Huxsoll,
R. H. Marchwicki, and A. J. Strano.
1975.
Recovery and characterization of a coronavirus from military dogs with diarrhea.
Proc. Annu. Meet. U. S. Anim. Health Assoc.
78:359-366.
|
| 3.
| Carmichael, L. E. 1978. Infectious canine
enteritis caused by corona-like virus: current status and request for
information. Baker Inst. Lab. Report. Series 2, number 9.
|
| 4.
|
Crandell, R. A.,
C. G. Fabricant, and W. A. Nelson Rees.
1973.
Development, characterisation, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK).
In Vitro
9:176-185[Medline].
|
| 5.
|
DeGroot, R. J., and M. C. Horzinek.
1995.
Feline infectious peritonitis, p. 293-315.
In
S. G. Siddell (ed.), The Coronaviridae. Plenum Press, New York, N.Y.
|
| 6.
|
Finlaison, D. S.
1995.
Faceal viruses of dogs an electron microscope study.
Vet. Microbiol.
46:295-305[CrossRef][Medline].
|
| 7.
|
Gamble, D. A.,
A. Lobbiani,
M. Gramegna,
L. E. Moore, and G. Colucci.
1997.
Development of a nested PCR assay for detection of feline infectious peritonitis virus in clinical specimens.
J. Clin. Microbiol.
35:673-675[Abstract].
|
| 8.
|
Gaskell, R. M.,
C. J. Gaskell,
D. E. Dennis, and M. J. A. Wooldbridge.
1982.
Efficacy of an inactivated feline calicivirus (FCV) vaccine against challenge with United Kingdom strains and its interaction with the FCV carrier state.
Res. Vet. Sci.
32:23-26[Medline].
|
| 9.
|
Herrewegh, A. A. P. M.,
I. Smeenk,
M. C. Horzinek,
P. J. M. Rottier, and R. J. de Groot.
1998.
Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus.
J. Virol.
72:4508-4514[Abstract/Free Full Text].
|
| 10.
|
Jiang, X.,
J. Wang,
D. Y. Graham, and M. K. Estes.
1992.
Detection of Norwalk virus in stool by polymerase chain reaction.
J. Clin. Microbiol.
30:2529-2534[Abstract/Free Full Text].
|
| 11.
|
Kokubu, T.,
S. Taharaguchi,
S. Katayama,
M. Hatano,
T. Takahashi,
K. Iwamoto,
K. Masubuchi,
M. Yamanaka,
O. Sasaki, and Y. Inaba.
1998.
Nucleotide sequence of the spike protein of canine coronavirus strain 5821.
J. Jpn. Vet. Med. Assoc.
51:251-255.
|
| 12.
|
Lai, M. M. C.,
R. C. Baric,
S. Makino,
J. G. Keck,
J. Engbert,
J. L. Leibowitz, and S. A. Stohlman.
1985.
Recombination between nonsegmented RNA genomes of murine coronavirus.
J. Virol.
56:449-456[Abstract/Free Full Text].
|
| 13.
|
Makino, S.,
J. G. Keck,
S. A. Stohlman, and M. M. C. Lai.
1986.
High-frequency RNA recombination of murine coronavirus.
J. Virol.
57:729-739[Abstract/Free Full Text].
|
| 14.
|
Marshall, J. A.,
D. S. Healy,
M. J. Studdert,
P. C. Scott,
M. L. Kennett,
B. K. Ward, and I. D. Gust.
1984.
Viruses and virus-like particles in the faeces of dogs with and without diarrhoea.
Aust. Vet. J.
61:33-38[Medline].
|
| 15.
|
Mochizuki, M.,
R. Sugiura, and M. Akuzawa.
1987.
Micro-neutralization test with canine coronavirus for detection of coronavirus antibodies in dogs and cats.
Jpn. J. Vet. Sci.
49:563-565.
|
| 16.
|
Naylor, M. J.,
R. P. Monckton,
P. R. Lehrbach, and E. M. Deane.
2001.
Canine coronavirus in Austalian dogs.
Aust. Vet. J.
79:27-30.
|
| 17.
|
Pratelli, A.,
M. Tempesta,
G. Greco,
V. Martella, and C. Buonavoglia.
1999.
Development of a nested PCR for the detection of canine coronavirus.
J. Virol. Methods
80:11-15[CrossRef][Medline].
|
| 18.
|
Pratelli, A.,
D. Buonavoglia,
V. Martella,
M. Tempesta,
A. Lavazza, and C. Buonavoglia.
2000.
Diagnosis of canine coronavirus infection using nested-PCR.
J. Virol. Methods
84:91-94[CrossRef][Medline].
|
| 19.
|
Rimmelzwaan, G. F.,
J. Groen,
H. Egberink,
G. H. A. Borst,
F. G. C. M. UytdeHaag, and A. D. M. E. Osterhaus.
1991.
The use of enzyme-linked immunosorbent assay systems for serology and antigen detection in parvovirus, coronavirus and rotavirus infections in dogs in The Netherlands.
Vet. Microbiol.
26:25-40[CrossRef][Medline].
|
| 20.
|
Saif, L. J.
1993.
Coronavirus immunogens.
Vet. Microbiol.
37:285-297[CrossRef][Medline].
|
| 21.
|
Schnagl, R. D., and I. H. Holmes.
1978.
Coronavirus-like particles in stools from dogs, from some country areas of Australia.
Vet. Rec.
102:528-529[Medline].
|
| 22.
|
Schunck, B.,
W. Kraft, and U. Truyen.
1995.
A simple touch-down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces.
J. Virol. Methods
55:427-433[CrossRef][Medline].
|
| 23.
|
Spaan, W. J. M.,
D. Cavanagh, and M. C. Horzinek.
1988.
Coronaviruses: structure and genome expression.
J. Gen. Virol.
69:2939-2952[Abstract/Free Full Text].
|
| 24.
|
Tennant, B. J.,
R. M. Gaskell,
R. C. Jones, and C. J. Gaskell.
1991.
Prevalence of antibodies to four major canine viral disease in dogs in a Liverpool hospital population.
J. Small Anim. Pract.
32:175-179.
|
| 25.
|
Tennant, B. J.,
R. M. Gaskell,
R. C. Jones, and C. J. Gaskell.
1993.
Studies on the epizootiology of canine coronavirus.
Vet. Rec.
132:7-11[Abstract].
|
| 26.
|
Tennant, B. J.,
R. M. Gaskell,
D. F. Kelly, and S. D. Carter.
1991.
Canine coronavirus infection in the dog following oronasal inoculation.
Res. Vet. Sci.
51:11-18[Medline].
|
| 27.
|
Tuchiya, K.,
T. Horimoto,
M. Azetaka,
E. Takahashi, and S. Konishi.
1991.
Enzyme-linked immunosorbent assay for the detection of canine coronavirus and its antibody in dogs.
Vet. Microbiol.
26:41-51[CrossRef][Medline].
|
| 28.
|
Uwatoka, K.,
M. Sunairi,
M. Nakajima, and K. Yamaura.
1995.
Rapid method utilizing the polymerase chain reaction for detection of canine parvovirus in feces of diarrheic dogs.
Vet. Microbiol.
43:315-323[CrossRef][Medline].
|
| 29.
|
Wesley, R. D.
1999.
The S gene of canine coronavirus, strain UCD-1, is more closely related to the S gene of transmissible gastroenteritis virus than to that of feline infectious peritonitis virus.
Virus Res.
61:145-152[CrossRef][Medline].
|
| 30.
|
Wesseling, J. G.,
H. Vennema,
G. J. Godeke,
M. C. Horzinek, and P. J. M. Rottier.
1994.
Nucleotide sequence and expression of the spike (S) gene of canine coronavirus and comparison with S proteins of feline and porcine coronaviruses.
J. Gen. Virol.
75:1789-1794[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, March 2001, p. 1036-1041, Vol. 39, No. 3
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1036-1041.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Naylor, M. J., Walia, C. S., McOrist, S., Lehrbach, P. R., Deane, E. M., Harrison, G. A.
(2002). Molecular Characterization Confirms the Presence of a Divergent Strain of Canine Coronavirus (UWSMN-1) in Australia. J. Clin. Microbiol.
40: 3518-3522
[Abstract]
[Full Text]